October 2025
-
Press release
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CMLIf approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix…
-
Press release
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two…
September 2025
-
Ad hoc release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled…
-
Statement
Bringing breakthroughs to more patients
-
Press release
Novartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the USSelect units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025DTP offering to expand to other appropriate products;…
-
Press release
Novartis announces commencement of tender offer to acquire Tourmaline BioBasel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender…
-
Press release
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPCNATALEE five-…
-
Press release
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapiesARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after…
-
Press release
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular diseasePacibekitug is a…
August 2025
-
Press release
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle painV-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1 85%…
-
Press release
New Novartis ESC data highlights strength of cardiovascular portfolioTwo VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol lowering monotherapyLp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing…
-
Press release
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failureIanalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients…